The Drug Enforcement Administration (DEA) has launched a significant hearing focused on the rescheduling of cannabis. During the first day, both the DEA and the Food and Drug Administration (FDA) underscored the comparative safety of marijuana relative to alcohol and opioids. However, the hearing has attracted criticism, with some arguing that it prioritizes politics over scientific evidence. The implications of federal cannabis reclassification are widespread, affecting states like Arizona and involving concerns regarding patient access and voices in the debate. Activists have raised alarms that their perspectives on legalization are being sidelined, pushing for greater transparency in the proceedings. The discussion is set against a backdrop of political donations influencing the rescheduling process and longstanding debates regarding the medical value of marijuana.